Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price123.96 USD
Fair value124.00
Ethical score70.0/100
Our investment reviews on this name
2026-09-08Read Markup123.96+0.0% to today ✓
2026-07-02Read Accumulation123.25+0.6% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Nuvalent, Inc. holds its Markup at $123.96. The statistical read favours the sellers, held for 97 days.
As held on the ledger · 2026-10-01
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 97 days
Price at the screen
$123.96
Valuation
N/A trailing · -30.85 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.14
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
78.59%
Below 33%
Interest-bearing cash and securities are 78.6% of assets, above the one-third limit.
Fail
Receivables
18.53%
Below 49%
Money owed to the company is 18.5% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Nuvalent,'s business is fine, but its cash and interest-bearing securities are about 79% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-01 screen. The gold marker is the market price at the same screen. A 0.0% margin of safety to the base estimate.
Reading the gap · Our model and the Street both land near the screened price: fairly valued, with no strong edge either way.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical stage cancer drug bets rarely pay off
A small lab team in Boston is racing to outsmart lung cancer mutations that keep dodging existing pills. Nuvalent sits at that early, all-or-nothing stage where one successful trial can lift everything and one setback wipes the slate clean.
We pass. The shares already sit at our fair value with no margin of safety, the company burns cash, posts zero profit and a deeply negative return on equity, and our ethical screen lacks enough data to clear it. Nine analysts simply call it a hold.
The real risk is the usual biotech cliff: trial failure, fresh dilution, or a long wait for any revenue. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NUVL trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markup$123.96+0.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 55%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it strong buy, with a mean price target of $145.
2026-09-08Markup · changed$123.96+0.0%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 55%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it strong buy, with a mean price target of $145.
2026-08-07Accumulation$123.96+0.6%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 55%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it strong buy, with a mean price target of $145.
2026-07-18Accumulation$123.25+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 55%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it strong buy, with a mean price target of $145.
2026-07-03Accumulation$123.25+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$123.25Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
